• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

  • — 14 Dec, 2007
AudioMedica News
AudioMedica News
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
00:00 /
RSS Feed
Share
Link
Embed
Stephen Jones
Stephen Jones

STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071213_stephen_jones.mp3]

You may also like...

  • ASCO Audio Journal of Oncology – August 1st 2006 ASCO Audio Journal of Oncology – August 1st 2006 30 Jul, 2006
  • Cora Sternberg Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too 24 Mar, 2013
  • ASCO Audio Journal of Oncology in Advance – February 15th, 2007 – reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007 ASCO Audio Journal of Oncology in Advance – February 15th, 2007 – reporting from San Antonio Breast Cancer Symposium, December 13-17, 2007 16 Feb, 2007
  • Mandeep Mehra MD COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey 28 May, 2020
  • Previous story Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
  • Next story AACR In New Partnership For San Antonio Breast Cancer Symposium
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
    • Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per…
  • Home
  • Oncology
  • Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.